|
|
|
|
|||||
|
|
|
Teleflex Incorporated TFX posted third-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $3.67, up 5.2% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 8.6%.
GAAP loss per share was $9.24 compared to EPS of $2.36 in the prior-year period.
Net revenues were up 19.4% year over year to $913 million. The metric surpassed the Zacks Consensus Estimate by 2%.
Following the announcement, shares of the company fell 0.8% last Friday.
Teleflex has three reportable segments — Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific).
Net revenues in the Americas were $555.9 million, which increased 7.8% from the year-ago period’s level. This compares with our model’s projection of $588.6 million for the quarter.
The EMEA (Europe, the Middle East and Africa) net revenues of $234.2 million increased 55.9% year over year. Our model projected revenues of $162.6 million for the quarter.
Revenues from Asia (Asia Pacific) rose 25% to $122.9 million. Our model’s projection was $142.1 million.
The Vascular Access segment recorded net revenues of $191 million, up 5.6% year over year. This compares with our model’s projection of $187.1 million.
The Interventional business registered net revenues of $266.4 million, up 77.8% year over year. This compares with our model’s projection of $260.3 million.
Within the Anesthesia segment, net revenues increased 0.4% year over year to $101.4 million. This compares with our model’s projection of $96.9 million.
The Surgical segment recorded net revenues of $122.9 million, up 10% year over year. Our model’s projection was $114.6 million.
Revenues from the Interventional Urology segment totaled $71.8 million, down 13.9% year over year. This compares with our model’s projection of $76.9 million.
OEM recorded revenue growth of $80.4 million, down 2.6% year over year. This compares with our model’s projection of $81 million.
The Other product segment’s (consisting of the company’s respiratory products not included in the divestiture to Medline, manufacturing service agreement revenues and Urology Care products) net revenues of $79.1 million reflected a year-over-year increase of 44.4%. This compares with our model’s projection of $76.4 million for the quarter.
The gross profit was $451.6 million, up 5% year over year. The gross margin contracted 681 basis points (bps) to 49.5% due to a 38% rise in the cost of goods sold.
Overall, the adjusted operating profit was $112.7 million, down 21.9% year over year. The adjusted operating margin contracted 652 bps to 12.3%.
Teleflex exited the third quarter of 2025 with cash and cash equivalents of $354 million compared with $253.7 million at the end of the second quarter.
Net cash flow provided by operating activities from continuing operations was $189 million compared with $435.6 million in the year-ago period.
Teleflex Incorporated price-consensus-eps-surprise-chart | Teleflex Incorporated Quote
GAAP revenue growth for 2025 is now expected to be in the range of 9.10-9.60% (down from the prior guidance of 9.00-10.00%). The Zacks Consensus Estimate for total revenues is pegged at $3.32 billion, indicating 8.9% growth year over year.
Teleflex now anticipates adjusted EPS from continuing operations to be in the range of $14.00-$14.20 (down from the prior guidance of $13.90-$14.30). The Zacks Consensus Estimate for EPS is pegged at $14.08.
Teleflex exited the third quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat estimates.
Interventional, Vascular Access, and Surgical businesses delivered strong growth, supported by robust demand for complex catheters, EZ-IO, and core surgical products. However, softness in Anesthesia and Interventional Urology, along with lower balloon pump orders, partially offset overall gains.
On a positive note, Teleflex completed the acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab.
On the flip side, a contraction of both the gross and adjusted margins does not bode well for the stock. Also, the company’s lowered 2025 guidance adds to the worry.
Teleflex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, IDEXX Laboratories IDXX and Boston Scientific BSX.
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 14.28%.
IDEXX, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $3.40, which exceeded the Zacks Consensus Estimate by 8.3%. Revenues of $1.11 billion topped the Zacks Consensus Estimate by 3.2%.
IDXX has an estimated historical earnings growth rate of 14.9% compared with the industry’s 10.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 6.08%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 2 hours | |
| 3 hours | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-11 | |
| Nov-11 | |
| Nov-11 | |
| Nov-11 | |
| Nov-11 | |
| Nov-10 | |
| Nov-10 | |
| Nov-10 | |
| Nov-07 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite